Evolutionary Genomics, Inc. (FNAM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 992.8 Thousand USD | -30.01% |
| 2021 | 2.87 Million USD | -0.5% |
| 2020 | 2.89 Million USD | 222.26% |
| 2019 | 897.51 Thousand USD | -5.69% |
| 2018 | 951.61 Thousand USD | -28.74% |
| 2017 | 1.33 Million USD | 4.73% |
| 2016 | 1.27 Million USD | 51.94% |
| 2015 | 839.2 Thousand USD | 3330.65% |
| 2014 | 24.46 Thousand USD | 68.62% |
| 2013 | 14.5 Thousand USD | 4.33% |
| 2012 | 13.9 Thousand USD | -19.81% |
| 2011 | 17.34 Thousand USD | -26.3% |
| 2010 | 23.52 Thousand USD | 46.86% |
| 2009 | 16.02 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q2 | - USD | 0.0% |
| 2022 Q2 | 531.43 Thousand USD | 1.24% |
| 2022 Q1 | 524.94 Thousand USD | -21.42% |
| 2022 Q4 | 412.24 Thousand USD | -24.45% |
| 2022 Q3 | 545.68 Thousand USD | 2.68% |
| 2022 FY | 2.01 Million USD | -30.01% |
| 2021 Q2 | 553.7 Thousand USD | 7.76% |
| 2021 FY | 2.87 Million USD | -0.5% |
| 2021 Q4 | 668.07 Thousand USD | -41.51% |
| 2021 Q3 | 1.14 Million USD | 106.3% |
| 2021 Q1 | 513.85 Thousand USD | -72.45% |
| 2020 Q1 | 242.31 Thousand USD | 2.9% |
| 2020 Q2 | 310.59 Thousand USD | 28.18% |
| 2020 Q3 | 474.5 Thousand USD | 52.77% |
| 2020 Q4 | 1.86 Million USD | 293.01% |
| 2020 FY | 2.89 Million USD | 222.26% |
| 2019 Q1 | 244.71 Thousand USD | 13.51% |
| 2019 Q2 | 222.08 Thousand USD | -9.25% |
| 2019 Q3 | 195.23 Thousand USD | -12.09% |
| 2019 Q4 | 235.48 Thousand USD | 20.62% |
| 2019 FY | 897.51 Thousand USD | -5.69% |
| 2018 FY | 951.61 Thousand USD | -28.74% |
| 2018 Q4 | 215.59 Thousand USD | -2.45% |
| 2018 Q1 | 242.43 Thousand USD | -7.43% |
| 2018 Q2 | 272.57 Thousand USD | 12.43% |
| 2018 Q3 | 221.01 Thousand USD | -18.92% |
| 2017 FY | 1.33 Million USD | 4.73% |
| 2017 Q4 | 261.88 Thousand USD | -2.41% |
| 2017 Q3 | 268.36 Thousand USD | 4.73% |
| 2017 Q2 | 256.23 Thousand USD | -53.31% |
| 2017 Q1 | 548.83 Thousand USD | 31.54% |
| 2016 FY | 1.27 Million USD | 51.94% |
| 2016 Q1 | 255.23 Thousand USD | -68.56% |
| 2016 Q2 | 304.05 Thousand USD | 19.13% |
| 2016 Q3 | 266.43 Thousand USD | -12.37% |
| 2016 Q4 | 417.24 Thousand USD | 56.6% |
| 2015 Q1 | 7531.00 USD | 44.83% |
| 2015 Q2 | 7432.00 USD | -1.31% |
| 2015 Q3 | 12.31 Thousand USD | 65.66% |
| 2015 FY | 839.2 Thousand USD | 3330.65% |
| 2015 Q4 | 811.93 Thousand USD | 6494.63% |
| 2014 FY | 24.46 Thousand USD | 68.62% |
| 2014 Q2 | 8975.00 USD | 704.93% |
| 2014 Q4 | 5200.00 USD | -43.31% |
| 2014 Q1 | 1115.00 USD | -49.39% |
| 2014 Q3 | 9172.00 USD | 2.19% |
| 2013 Q2 | 7667.00 USD | 224.46% |
| 2013 Q1 | 2363.00 USD | -7.15% |
| 2013 Q3 | 2274.00 USD | -70.34% |
| 2013 Q4 | 2203.00 USD | -3.12% |
| 2013 FY | 14.5 Thousand USD | 4.33% |
| 2012 FY | 13.9 Thousand USD | -19.81% |
| 2012 Q4 | 2545.00 USD | 17.5% |
| 2012 Q3 | 2166.00 USD | 21.89% |
| 2012 Q1 | 7418.00 USD | 260.45% |
| 2012 Q2 | 1777.00 USD | -76.04% |
| 2011 Q1 | 7244.00 USD | -38.32% |
| 2011 Q3 | 6120.00 USD | 218.92% |
| 2011 Q2 | 1919.00 USD | -73.51% |
| 2011 FY | 17.34 Thousand USD | -26.3% |
| 2011 Q4 | 2058.00 USD | -66.37% |
| 2010 FY | 23.52 Thousand USD | 46.86% |
| 2010 Q4 | 11.74 Thousand USD | 37.3% |
| 2010 Q1 | 483.00 USD | 34.54% |
| 2010 Q3 | 8554.00 USD | 211.51% |
| 2010 Q2 | 2746.00 USD | 468.53% |
| 2009 Q4 | 359.00 USD | 14.7% |
| 2009 FY | 16.02 Thousand USD | 0.0% |
| 2009 Q3 | 313.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -50.145% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | 89.288% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 96.69% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 98.521% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | 93.733% |
| Better Therapeutics, Inc. | 38.26 Million USD | 97.405% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 97.56% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | 91.989% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 97.067% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 97.116% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 99.085% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 96.954% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 97.885% |
| Innovation1 Biotech Inc. | 1.21 Million USD | 18.266% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | 95.021% |
| Molecular Templates, Inc. | 63.09 Million USD | 98.426% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | 92.874% |
| NexImmune, Inc. | 28.16 Million USD | 96.475% |
| Orgenesis Inc. | 45.75 Million USD | 97.83% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | 96.129% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -1252.306% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | 93.851% |
| Scopus BioPharma Inc. | 11.71 Million USD | 91.525% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 99.754% |
| Statera Biopharma, Inc. | 28.82 Million USD | 96.556% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | 94.755% |
| Trevena, Inc. | 38.41 Million USD | 97.415% |
| Vaxxinity, Inc. | 56.05 Million USD | 98.229% |
| Vaccinex, Inc. | 23.45 Million USD | 95.767% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | 5.174% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 98.042% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | 86.352% |